ICAD INC (ICAD) Fundamental Analysis & Valuation

NASDAQ:ICAD • US44934S2068

3.87 USD
+0.14 (+3.75%)
At close: Jul 16, 2025
3.87 USD
0 (0%)
After Hours: 7/16/2025, 8:16:17 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ICAD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

ICAD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. While ICAD has a great health rating, there are worries on its profitability. ICAD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. ICAD Profitability Analysis

1.1 Basic Checks

  • In the past year ICAD has reported negative net income.
  • ICAD had a negative operating cash flow in the past year.
  • ICAD had negative earnings in each of the past 5 years.
  • ICAD had a negative operating cash flow in each of the past 5 years.
ICAD Yearly Net Income VS EBIT VS OCF VS FCFICAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • ICAD has a Return On Assets of -13.24%. This is comparable to the rest of the industry: ICAD outperforms 58.33% of its industry peers.
  • The Return On Equity of ICAD (-16.98%) is better than 61.11% of its industry peers.
Industry RankSector Rank
ROA -13.24%
ROE -16.98%
ROIC N/A
ROA(3y)-17.69%
ROA(5y)-20.57%
ROE(3y)-24.41%
ROE(5y)-31.02%
ROIC(3y)N/A
ROIC(5y)N/A
ICAD Yearly ROA, ROE, ROICICAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • Looking at the Gross Margin, with a value of 85.57%, ICAD belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ICAD has grown nicely.
  • ICAD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5Y1.87%
ICAD Yearly Profit, Operating, Gross MarginsICAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ICAD Health Analysis

2.1 Basic Checks

  • ICAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ICAD has about the same amount of shares outstanding.
  • The number of shares outstanding for ICAD has been increased compared to 5 years ago.
  • There is no outstanding debt for ICAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ICAD Yearly Shares OutstandingICAD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ICAD Yearly Total Debt VS Total AssetsICAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • ICAD has an Altman-Z score of -1.89. This is a bad value and indicates that ICAD is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -1.89, ICAD is doing worse than 69.44% of the companies in the same industry.
  • There is no outstanding debt for ICAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.89
ROIC/WACCN/A
WACC10.6%
ICAD Yearly LT Debt VS Equity VS FCFICAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M 40M

2.3 Liquidity

  • A Current Ratio of 3.66 indicates that ICAD has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 3.66, ICAD belongs to the best of the industry, outperforming 80.56% of the companies in the same industry.
  • A Quick Ratio of 3.57 indicates that ICAD has no problem at all paying its short term obligations.
  • The Quick ratio of ICAD (3.57) is better than 80.56% of its industry peers.
Industry RankSector Rank
Current Ratio 3.66
Quick Ratio 3.57
ICAD Yearly Current Assets VS Current LiabilitesICAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ICAD Growth Analysis

3.1 Past

  • The earnings per share for ICAD have decreased strongly by -50.00% in the last year.
  • The Revenue has grown by 18.39% in the past year. This is quite good.
  • ICAD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.95% yearly.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)18.39%
Revenue growth 3Y-16.47%
Revenue growth 5Y-8.95%
Sales Q2Q%-1.61%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.99% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ICAD will show a small growth in Revenue. The Revenue will grow by 6.47% on average per year.
EPS Next Y12.57%
EPS Next 2Y20.06%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year4.66%
Revenue Next 2Y-2.38%
Revenue Next 3Y6.47%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ICAD Yearly Revenue VS EstimatesICAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
ICAD Yearly EPS VS EstimatesICAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

1

4. ICAD Valuation Analysis

4.1 Price/Earnings Ratio

  • ICAD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ICAD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICAD Price Earnings VS Forward Price EarningsICAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICAD Per share dataICAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • ICAD's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.06%
EPS Next 3Y25.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ICAD Dividend Analysis

5.1 Amount

  • ICAD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ICAD Fundamentals: All Metrics, Ratios and Statistics

ICAD INC

NASDAQ:ICAD (7/16/2025, 8:16:17 PM)

After market: 3.87 0 (0%)

3.87

+0.14 (+3.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-13
Earnings (Next)08-11
Inst Owners31.88%
Inst Owner Change-100%
Ins Owners5.51%
Ins Owner Change0%
Market Cap106.31M
Revenue(TTM)19.53M
Net Income(TTM)-5.23M
Analysts76
Price Target3.57 (-7.75%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)56.3%
Min EPS beat(2)43.98%
Max EPS beat(2)68.63%
EPS beat(4)4
Avg EPS beat(4)35.5%
Min EPS beat(4)11.77%
Max EPS beat(4)68.63%
EPS beat(8)8
Avg EPS beat(8)54.96%
EPS beat(12)9
Avg EPS beat(12)33.86%
EPS beat(16)9
Avg EPS beat(16)18.4%
Revenue beat(2)2
Avg Revenue beat(2)7.68%
Min Revenue beat(2)5.52%
Max Revenue beat(2)9.83%
Revenue beat(4)3
Avg Revenue beat(4)4.57%
Min Revenue beat(4)-8.54%
Max Revenue beat(4)11.48%
Revenue beat(8)5
Avg Revenue beat(8)-0.26%
Revenue beat(12)5
Avg Revenue beat(12)-10.55%
Revenue beat(16)5
Avg Revenue beat(16)-9.57%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)5.55%
EPS NQ rev (3m)1.44%
EPS NY rev (1m)10%
EPS NY rev (3m)18.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.44
P/FCF N/A
P/OCF N/A
P/B 3.45
P/tB 4.76
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.71
BVpS1.12
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.24%
ROE -16.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.57%
FCFM N/A
ROA(3y)-17.69%
ROA(5y)-20.57%
ROE(3y)-24.41%
ROE(5y)-31.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5Y1.87%
F-Score3
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.26%
Cap/Sales 0.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.66
Quick Ratio 3.57
Altman-Z -1.89
F-Score3
WACC10.6%
ROIC/WACCN/A
Cap/Depr(3y)118.09%
Cap/Depr(5y)108.13%
Cap/Sales(3y)2.69%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y12.57%
EPS Next 2Y20.06%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)18.39%
Revenue growth 3Y-16.47%
Revenue growth 5Y-8.95%
Sales Q2Q%-1.61%
Revenue Next Year4.66%
Revenue Next 2Y-2.38%
Revenue Next 3Y6.47%
Revenue Next 5YN/A
EBIT growth 1Y-10.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.42%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.59%
OCF growth 3YN/A
OCF growth 5YN/A

ICAD INC / ICAD FAQ

What is the ChartMill fundamental rating of ICAD INC (ICAD) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ICAD.


What is the valuation status of ICAD INC (ICAD) stock?

ChartMill assigns a valuation rating of 1 / 10 to ICAD INC (ICAD). This can be considered as Overvalued.


How profitable is ICAD INC (ICAD) stock?

ICAD INC (ICAD) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for ICAD stock?

The Earnings per Share (EPS) of ICAD INC (ICAD) is expected to grow by 12.57% in the next year.